Delgocitinib cream had superior efficacy and a better safety profile compared with oral alitretinoin for the treatment of ...

Tumor-infiltrating clonal hematopoiesis (TI-CH) increased the risk of disease recurrence or death among patients with early ...

The study’s small size limits interpretation, but it remains the largest real-world data available, experts said.

Repertoire Immune Medicines has signed a partnership and licence agreement with Genentech, focusing on T cell-targeted immune ...

A Bay Area biotech giant is receiving growing attention for its approach to a topic that has been historically stigmatized ...

Patients with advanced solid tumors experienced significantly improved survival outcomes when receiving a tailored therapy ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo's ...

Roche’s Genentech has inked a deal with Repertoire Immune Medicines aimed at discovering and developing T-cell-targeted ...

Roche’s Genentech is betting on the Flagship Pioneering–founded company’s discovery platform called DECODE to find new ...

The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital ...

Roche’s Genentech unit and Repertoire Immune Medicines have entered into a partnership worth $765m to discover and develop T ...